[ { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026", "title": "Kvartalsrapport Q1 2026", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/aab98738e2c5e633c3f51d1ff0cf52426", "date": "2026-05-06", "period": "2026-q1", "form_type": "interim-report", "report_key": "2026:q1", "filename": "IBT_Delarsrapport_Q1_2026_SWE.pdf", "text_chars": 25715, "sha256": "60547f958272dd40ba2712e07317218b73088891e55b691618e32cfdcb697788", "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026", "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026", "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt", "parts": [ { "number": 1, "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html", "chars": 25715 } ] }, { "doc_id": "nasdaq-nordic-arsredovisning-2025", "title": "Årsredovisning 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a8c22c84d7301089482c83358d64784a4", "date": "2026-03-27", "period": "2025-annual", "form_type": "annual-report", "report_key": "2025:annual", "filename": "IBT_AR_2025_SWE.pdf", "text_chars": 126960, "sha256": "57d5849913dcb69ecf4754806e59c338a346dfc9a40e3c06e522c8255e4d9c1a", "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2025", "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2025", "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/part-001.html", "chars": 126960 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025", "title": "Kvartalsrapport Q4 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a66490c3b1577450316a0e9ff1c7f1af0", "date": "2026-02-06", "period": "2025-q4", "form_type": "year-end-report", "report_key": "2025:q4", "filename": "IBT_Bokslutskommunike_Q4_2025_SWE.pdf", "text_chars": 23017, "sha256": "f0075fd94502b2a6d54a9ec3f7ad5ee50db8f09da508060f5cb663e1959987e9", "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025", "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025", "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html", "chars": 23017 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025", "title": "Kvartalsrapport Q3 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a917c68d40817e6683d3ddbe39cc8ede0", "date": "2025-11-13", "period": "2025-q3", "form_type": "interim-report", "report_key": "2025:q3", "filename": "IBT_Delarsrapport_Q3_2025_SWE.pdf", "text_chars": 28703, "sha256": "eff505bc2ee8be453261fe103f9076d941f5b9abd186965a5e2d4bdc2dac5505", "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025", "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025", "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html", "chars": 28703 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025", "title": "Kvartalsrapport Q2 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a1b435d92c4f4ae2608ff1bc2cd7539a3", "date": "2025-08-20", "period": "2025-q2", "form_type": "interim-report", "report_key": "2025:q2", "filename": "IBT_Delarsrapport_Q2_2025_SWE.pdf", "text_chars": 29386, "sha256": "cb1be1894b069461b3f76ae27243aa2c1e06a97909be21597672f49f865e7cbd", "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025", "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025", "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html", "chars": 29386 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025", "title": "Kvartalsrapport Q1 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a697a551aa54bc2748df37c10092bee28", "date": "2025-05-07", "period": "2025-q1", "form_type": "interim-report", "report_key": "2025:q1", "filename": "IBT_Delarsrapport_Q1_2025_SWE.pdf", "text_chars": 23394, "sha256": "254e2c7f46096af3ba99a4b04ad8190770155a87929019b5f91f29ad23f09e0e", "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025", "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025", "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html", "chars": 23394 } ] }, { "doc_id": "nasdaq-nordic-arsredovisning-2024", "title": "Årsredovisning 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a6f888496f180b76dd578e4bec19c9ca5", "date": "2025-03-27", "period": "2024-annual", "form_type": "annual-report", "report_key": "2024:annual", "filename": "IBT_AR_2024_SWE.pdf", "text_chars": 128182, "sha256": "e8ac50795bc8b094a5d257f04dfc2fd0ebaaa24f3678d4f1bf48188dc98dccbc", "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2024", "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2024", "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/part-001.html", "chars": 128182 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024", "title": "Kvartalsrapport Q4 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a75ff970d41a7f900c40093f0e44f40ca", "date": "2025-02-13", "period": "2024-q4", "form_type": "year-end-report", "report_key": "2024:q4", "filename": "IBT_Bokslutskommunike_2024_SWE.pdf", "text_chars": 28388, "sha256": "60673f59815137502ce0484f4dff8728d5b74a7739ce3cc53291776654892714", "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024", "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024", "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html", "chars": 28388 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024", "title": "Kvartalsrapport Q3 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ac8f2b73a9b8bf06d95baa057ee338fc3", "date": "2024-11-14", "period": "2024-q3", "form_type": "interim-report", "report_key": "2024:q3", "filename": "IBT_Q3_2024_SWE.pdf", "text_chars": 31917, "sha256": "8fa6fb15345a38a89d633e003181c4d9316286be92b6fe92e2ee91ea19dfdb52", "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024", "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024", "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html", "chars": 31917 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024", "title": "Kvartalsrapport Q2 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a0cc900329bea0b4d50080bd6355bda22", "date": "2024-08-28", "period": "2024-q2", "form_type": "interim-report", "report_key": "2024:q2", "filename": "IBT_Q2_2024_SWE.pdf", "text_chars": 30065, "sha256": "828207bdc489450224f095a0e200679a215d28b9d73bdc3f17a46a77068ee59b", "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024", "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024", "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html", "chars": 30065 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024", "title": "Kvartalsrapport Q1 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/af20d6c8b8ab9d41a8631f94b247f5b51", "date": "2024-05-07", "period": "2024-q1", "form_type": "interim-report", "report_key": "2024:q1", "filename": "IBT_Q1_2024_SWE.pdf", "text_chars": 27735, "sha256": "6ed837bdc6bdb7a412198cd615dc48f759cf9381b4e368d1d10d666e84a49bc1", "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024", "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024", "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html", "chars": 27735 } ] }, { "doc_id": "nasdaq-nordic-arsredovisning-2023", "title": "Årsredovisning 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a83118a0ffca658a51b7661b06f9d367b", "date": "2024-03-25", "period": "2023-annual", "form_type": "annual-report", "report_key": "2023:annual", "filename": "IBT_Arsredovisning_2023.pdf", "text_chars": 143392, "sha256": "e0e4c6cdf0708d6b045abc77f70fe01082123b17c52426cdd1cd9b385347ca0c", "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2023", "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2023", "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/part-001.html", "chars": 143392 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023", "title": "Kvartalsrapport Q4 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a32e4c171dc57857ab695a042d279a1ad", "date": "2024-02-08", "period": "2023-q4", "form_type": "year-end-report", "report_key": "2023:q4", "filename": "IBT_Bokslutskommumike_2023_SWE.pdf", "text_chars": 36086, "sha256": "0d62610a160ae9194d24a678fc256c4156241f31155955b7ddd6ebee83312994", "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023", "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023", "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html", "chars": 36086 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023", "title": "Kvartalsrapport Q3 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/acbf891c15f9e41312f319d0ddc1594b3", "date": "2023-11-10", "period": "2023-q3", "form_type": "interim-report", "report_key": "2023:q3", "filename": "IBT_Q3_2023_SWE.pdf", "text_chars": 39437, "sha256": "f05f5d227315ed3ee516f2036ecf70a3ffbd03bf221bb18effe2dd19f6987e40", "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023", "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023", "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html", "chars": 39437 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023", "title": "Kvartalsrapport Q2 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ab00cd4908db4148bfe82b553f3543eba", "date": "2023-08-25", "period": "2023-q2", "form_type": "interim-report", "report_key": "2023:q2", "filename": "IBT_Q2_2023_SWE.pdf", "text_chars": 35246, "sha256": "4dfb488ba5020d824c3e34b05c4e7f98e2e5239bdfc522ec7c0276ecec505a8a", "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023", "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023", "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html", "chars": 35246 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023", "title": "Kvartalsrapport Q1 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ae1ad6598b6277e4600d2810e334d2c8f", "date": "2023-05-08", "period": "2023-q1", "form_type": "interim-report", "report_key": "2023:q1", "filename": "IBT_Q1_2023_SWE.pdf", "text_chars": 28232, "sha256": "ab30a5ae58ec8f12c3625d739c21cd62e25f33078af1b4aba15c0931ed6806bc", "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023", "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023", "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html", "chars": 28232 } ] }, { "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata", "title": "MFN bolagssida och bolagsmetadata", "source": "MFN", "source_class": "mfn", "source_url": "https://mfn.se/all/a/infant-bacterial-therapeutics", "date": null, "period": null, "form_type": "company-page", "report_key": null, "filename": "company.txt", "text_chars": 12936, "sha256": "b2dfe019cedecef56729e8f0e043bac03afdb398358b1e767744140ecc5c3243", "url": "/company/infant-bacterial-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata", "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata", "txt_url": "/company/infant-bacterial-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt", "parts": [ { "number": 1, "url": "/company/infant-bacterial-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html", "chars": 12936 } ] } ]